Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Veracyte (VCYT) Research & Development (2016 - 2025)

Veracyte (VCYT) has disclosed Research & Development for 14 consecutive years, with $20.8 million as the latest value for Q4 2025.

  • Quarterly Research & Development rose 8.08% to $20.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $70.8 million through Dec 2025, up 2.19% year-over-year, with the annual reading at $70.8 million for FY2025, 2.19% up from the prior year.
  • Research & Development hit $20.8 million in Q4 2025 for Veracyte, up from $16.0 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $20.8 million in Q4 2025 to a low of $5.3 million in Q1 2021.
  • Historically, Research & Development has averaged $13.4 million across 5 years, with a median of $13.0 million in 2023.
  • Biggest five-year swings in Research & Development: skyrocketed 123.55% in 2021 and later decreased 9.06% in 2025.
  • Year by year, Research & Development stood at $10.3 million in 2021, then increased by 10.1% to $11.3 million in 2022, then soared by 65.44% to $18.7 million in 2023, then rose by 3.3% to $19.3 million in 2024, then increased by 8.08% to $20.8 million in 2025.
  • Business Quant data shows Research & Development for VCYT at $20.8 million in Q4 2025, $16.0 million in Q3 2025, and $16.3 million in Q2 2025.